ADCs have achieved great clinical successes in recent years. However, ADC therapies still face challenges in responses, resistance, and serious side effects that limit their therapeutic windows. To address these concerns, we developed bispecific ADCs (bsADCs) that target two TAAs simultaneously. The bispecific targeting moiety is based on our proprietary, fully human, common light chain bispecific antibody platform (RenLite®). We generated such common light chain antibodies against over two hundred TAAs, which may be used in a plug-and-play manner to form bispecific ADCs based on the biology of the targets. Over twenty bsADCs are in various discovery and development stages at Biocytogen. In this poster, we present YH013 (an EGFR x MET bsADC) as an example of our approach. We show YH013 binds preferentially to cells positive for both antigens, internalizes more efficiently, and demonstrates superior inhibition of tumor growth in preclinical models as opposed to their parental monoclonal ADCs.